Xenetic Biosciences Property, Plant, and Equipment 2013-2026 | XBIO

Xenetic Biosciences property, plant, and equipment from 2013 to 2026. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Xenetic Biosciences Annual Property, Plant, and Equipment
(Millions of US $)
2025
2024
2023
2022
2021
2020
2019 $0
2018 $0
2017 $0
2016 $0
2015 $0
2014 $0
2013 $0
2012 $0
2011 $0
Xenetic Biosciences Quarterly Property, Plant, and Equipment
(Millions of US $)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $0
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30
2013-06-30
2013-03-31
2012-12-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.007B $0.003B
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $76.559B 25.84
UCB SA (UCBJY) Belgium $53.468B 0.00
Takeda Pharmaceutical (TAK) Japan $49.234B 8.99
Sandoz Group AG (SDZNY) Switzerland $37.752B 0.00
Otsuka Holdings, - (OTSKY) Japan $35.394B 13.90
Zoetis (ZTS) United States $31.815B 11.73
BeOne Medicines - (ONC) Switzerland $29.822B 60.81
Daiichi Sankyo, - (DSNKY) Japan $29.359B 16.77
Astellas Pharma (ALPMY) Japan $24.376B 9.16
United Therapeutics (UTHR) United States $22.849B 19.87
Merck (MKKGY) Germany $19.748B 13.58
Neurocrine Biosciences (NBIX) United States $16.251B 27.21
IPSEN (IPSEY) France $15.217B 0.00
Shionogi (SGIOY) Japan $14.807B 10.88
Ionis Pharmaceuticals (IONS) United States $12.542B 0.00
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $11.965B 15.63
Madrigal Pharmaceuticals (MDGL) United States $11.825B 0.00
Summit Therapeutics (SMMT) United States $11.084B 0.00
Orion OYJ (ORINY) Finland $10.968B 17.83
Corcept Therapeutics (CORT) United States $8.557B 227.74
Eisai (ESAIY) $7.000B 0.00
Ono Pharmaceutical (OPHLF) Japan $6.344B 13.64
Centessa Pharmaceuticals (CNTA) United Kingdom $6.217B 0.00
Oruka Therapeutics (ORKA) United States $5.149B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $5.139B 19.65
Stevanato Group S.p.A (STVN) Italy $5.130B 27.32
Grifols, S.A (GRFS) Spain $4.955B 0.00
Indivior Pharmaceuticals (INDV) United States $4.672B 12.73
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.280B 0.00
Catalyst Pharmaceuticals (CPRX) United States $3.842B 11.89
Crinetics Pharmaceuticals (CRNX) United States $3.730B 0.00
Definium Therapeutics (DFTX) United States $3.656B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $3.603B 0.00
Dyne Therapeutics (DYN) United States $3.450B 0.00
Relay Therapeutics (RLAY) United States $3.311B 0.00
Enliven Therapeutics (ELVN) United States $2.799B 0.00
Hypermarcas (HYPMY) Brazil $2.753B 8.15
Soleno Therapeutics (SLNO) United States $2.717B 228.83
BioCryst Pharmaceuticals (BCRX) United States $2.323B 7.03
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.254B 19.48
Nektar Therapeutics (NKTR) United States $2.220B 0.00
Ocular Therapeutix (OCUL) United States $2.183B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $2.113B 0.00
Guardian Pharmacy Services (GRDN) United States $2.085B 41.89
Amylyx Pharmaceuticals (AMLX) United States $1.810B 0.00
Harrow (HROW) United States $1.581B 212.05
Ardelyx (ARDX) United States $1.574B 0.00
Aktis Oncology (AKTS) United States $1.324B 0.00
Xeris Biopharma Holdings (XERS) United States $1.191B 115.00
Savara (SVRA) United States $1.166B 0.00
Collegium Pharmaceutical (COLL) United States $1.085B 4.86
Xencor (XNCR) United States $1.039B 0.00
KalVista Pharmaceuticals (KALV) United States $0.993B 0.00
ARS Pharmaceuticals (SPRY) United States $0.991B 0.00
Cronos Group (CRON) Canada $0.989B 0.00
Evotec AG (EVO) Germany $0.932B 0.00
Avalo Therapeutics (AVTX) United States $0.898B 0.00
Theravance Biopharma (TBPH) United States $0.854B 17.25
Esperion Therapeutics (ESPR) United States $0.814B 0.00
Zevra Therapeutics (ZVRA) United States $0.748B 9.96
Bioventus (BVS) United States $0.734B 11.72
Relmada Therapeutics (RLMD) United States $0.723B 0.00
Aclaris Therapeutics (ACRS) United States $0.676B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.661B 5.65
Ironwood Pharmaceuticals (IRWD) United States $0.623B 6.26
Aquestive Therapeutics (AQST) United States $0.592B 0.00
Altimmune (ALT) United States $0.570B 0.00
ProKidney (PROK) United States $0.550B 0.00
4D Molecular Therapeutics (FDMT) United States $0.545B 0.00
Achieve Life Sciences (ACHV) Canada $0.524B 0.00
Indaptus Therapeutics (INDP) United States $0.427B 0.00
Century Therapeutics (IPSC) United States $0.415B 0.00
Lexeo Therapeutics (LXEO) United States $0.396B 0.00
Elite Pharmaceuticals (ELTP) United States $0.390B 36.25
Larimar Therapeutics (LRMR) United States $0.380B 0.00
Nature's Sunshine Products (NATR) United States $0.359B 15.57
Silence Therapeutics (SLN) United Kingdom $0.356B 0.00
USANA Health Sciences (USNA) United States $0.349B 10.50
Prelude Therapeutics (PRLD) United States $0.344B 0.00
OmniAb (OABI) United States $0.336B 0.00
Organogenesis (ORGO) United States $0.313B 81.00
Siga Technologies (SIGA) United States $0.311B 16.04
Akebia Therapeutics (AKBA) United States $0.292B 0.00
Lyell Immunopharma (LYEL) United States $0.279B 0.00
Surrozen (SRZN) United States $0.275B 0.00
Cybin (HELP) Canada $0.250B 0.00
Inhibikase Therapeutics (IKT) United States $0.243B 0.00
Profound Medical (PROF) Canada $0.238B 0.00
Protara Therapeutics (TARA) United States $0.231B 0.00
Minerva Neurosciences (NERV) United States $0.217B 0.00
Unicycive Therapeutics (UNCY) United States $0.216B 0.00
Karyopharm Therapeutics (KPTI) United States $0.204B 0.00
Korro Bio (KRRO) United States $0.200B 0.00
AleAnna (ANNA) United States $0.195B 20.93
Tonix Pharmaceuticals Holding (TNXP) United States $0.194B 0.00
Galectin Therapeutics (GALT) United States $0.184B 0.00
MediWound (MDWD) Israel $0.179B 0.00
Journey Medical (DERM) United States $0.177B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.154B 0.00
Enlivex (ENLV) Israel $0.148B 0.00
Rafael Holdings (RFL) United States $0.143B 0.00
NRx Pharmaceuticals (NRXP) United States $0.141B 0.00
Innate Pharma SA (IPHYF) France $0.138B 0.00
Fractyl Health (GUTS) United States $0.138B 0.00
Pyxis Oncology (PYXS) United States $0.135B 0.00
Veraxa Biotech AG (VRXA) United States $0.131B 0.00
VAXART, INC (VXRT) United States $0.130B 3.57
Avita Medical (RCEL) United States $0.124B 0.00
Aldeyra Therapeutics (ALDX) United States $0.124B 0.00
Cardiol Therapeutics (CRDL) Canada $0.122B 0.00
Assertio Holdings (ASRT) United States $0.116B 0.00
Cassava Sciences (SAVA) United States $0.101B 0.00
PolyPid (PYPD) Israel $0.098B 0.00
Vivani Medical (VANI) United States $0.097B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.097B 0.00
China SXT Pharmaceuticals (SXTC) China $0.091B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.090B 0.00
Telomir Pharmaceuticals (TELO) United States $0.088B 0.00
Champions Oncology (CSBR) United States $0.087B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.083B 0.00
Heron Therapeutics (HRTX) United States $0.081B 0.00
Gain Therapeutics (GANX) United States $0.079B 0.00
Dominari Holdings (DOMH) United States $0.072B 0.00
Acrivon Therapeutics (ACRV) United States $0.068B 0.00
ElectroCore (ECOR) United States $0.067B 0.00
PMV Pharmaceuticals (PMVP) United States $0.061B 0.00
Context Therapeutics (CNTX) United States $0.058B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.058B 0.00
Alaunos Therapeutics (TCRT) United States $0.053B 0.00
Talphera (TLPH) United States $0.051B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Incannex Healthcare (IXHL) Australia $0.039B 0.00
Nutriband (NTRB) United States $0.038B 0.00
SCYNEXIS (SCYX) United States $0.038B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
Lite Strategy (LITS) United States $0.030B 0.00
Plus Therapeutics (PSTV) United States $0.027B 0.00
TherapeuticsMD (TXMD) United States $0.023B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.023B 0.00
VYNE Therapeutics (VYNE) United States $0.022B 0.00
Lipocine (LPCN) United States $0.019B 0.00
Tempest Therapeutics (TPST) United States $0.019B 0.00
Klotho Neurosciences (KLTO) United States $0.016B 0.00
Citius Pharmaceuticals (CTXR) United States $0.016B 0.00
Natural Alternatives (NAII) United States $0.016B 0.00
Scienture Holdings (SCNX) United States $0.016B 0.00
Vyome Holdings (HIND) United States $0.015B 0.00
Iterum Therapeutics (ITRM) Ireland $0.015B 0.00
BioVie (BIVI) United States $0.015B 0.00
BioLineRx (BLRX) Israel $0.014B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.011B 0.00
CASI Pharmaceuticals (CASI) China $0.010B 0.00
Mannatech (MTEX) United States $0.010B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.009B 0.00
Jupiter Neurosciences (JUNS) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.008B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Inotiv (NOTV) United States $0.008B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.008B 0.00
Wellgistics Health (WGRX) United States $0.008B 0.00
CDT Equity (CDT) United States $0.007B 0.00
Ernexa Therapeutics (ERNA) United States $0.007B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Heatwurx (PCSA) United States $0.006B 0.00
Biomerica (BMRA) United States $0.006B 0.00
Vivos Therapeutics (VVOS) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Liminatus Pharma (LIMN) United States $0.005B 0.00
Mangoceuticals (MGRX) United States $0.005B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
TransCode Therapeutics (RNAZ) United States $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
SciSparc (SPRC) Israel $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
Clearmind Medicine (CMND) Canada $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
Jaguar Animal Health (JAGX) United States $0.002B 0.00
PainReform (PRFX) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00